Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

NCT00782561 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Segmental Glomerulosclerosis

Interventions

DRUG: FG-3019

Sponsor

Kyntra Bio